APA (7th ed.) Citation

Heinze, A., Afridi, S. K., Totev, T., Krasenbaum, L. J., Terasawa, E., Akcicek, H., . . . Driessen, M. T. (2026). Real-World Clinical Effectiveness and Migraine-Related Healthcare Resource Utilization in Patients Initiating Fremanezumab in Germany and the United Kingdom. Therapeutics & Clinical Risk Management, 22, 1. https://doi.org/10.2147/TCRM.S529550

Chicago Style (17th ed.) Citation

Heinze, Axel, et al. "Real-World Clinical Effectiveness and Migraine-Related Healthcare Resource Utilization in Patients Initiating Fremanezumab in Germany and the United Kingdom." Therapeutics & Clinical Risk Management 22 (2026): 1. https://doi.org/10.2147/TCRM.S529550.

MLA (9th ed.) Citation

Heinze, Axel, et al. "Real-World Clinical Effectiveness and Migraine-Related Healthcare Resource Utilization in Patients Initiating Fremanezumab in Germany and the United Kingdom." Therapeutics & Clinical Risk Management, vol. 22, 2026, p. 1, https://doi.org/10.2147/TCRM.S529550.